Silexion Therapeutics Corp has successfully navigated a significant hurdle by receiving a favorable decision from a Nasdaq Hearings Panel, which allows the company to maintain its listing on the Nasdaq Capital Market. This decision, made on November 18, 2026, comes after Silexion appealed Nasdaq's earlier determination regarding its non-compliance with the minimum shareholders' equity requirement and the minimum bid price requirement.

The ruling is crucial for Silexion as it continues to develop its position in the competitive biological products industry. The company must now adhere to specific conditions set forth by the Hearings Panel to ensure it remains compliant with Nasdaq's listing standards.

Background

Silexion Therapeutics Corp, incorporated in the Cayman Islands, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances (SIC 2836). The company trades on the Nasdaq under the ticker symbols SLXN and SLXNW. Recent filings indicate that Silexion is classified as an emerging growth company.

What the Filing Says

According to the SEC filing (accession number 0001178913-26-005294), the Hearings Panel's decision requires Silexion to:

  • Complete a planned private placement financing for net proceeds of $2.5 million by December 4, 2026, to demonstrate compliance with the minimum shareholders' equity requirement.
  • Maintain a closing bid price of at least $1.00 per share for ten consecutive trading days by November 24, 2026.
  • Complete a public offering of at least $5 million by March 31, 2027.

Furthermore, the company must maintain compliance with all Nasdaq listing requirements through May 15, 2027. Failure to meet any of these conditions could result in immediate delisting.

Impact

This decision impacts Silexion's investors and stakeholders, as the company must now work diligently to meet the outlined conditions to avoid delisting. The ruling also highlights the challenges faced by emerging growth companies in the biological products sector, where compliance with regulatory and market standards is critical for survival and growth.

What's Next

Moving forward, Silexion must focus on fulfilling the conditions set by the Nasdaq Hearings Panel. The filing does not specify what happens next if the company fails to comply with these requirements, leaving uncertainty about its future listing status.